Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease

...ar stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). rapamune is a trademark of Wyeth Pharmaceuticals. ...

Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent

...ar stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). rapamune is a trademark of Wyeth Pharmaceuticals. ...

Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent

...ar stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). rapamune is a trademark of Wyeth Pharmaceuticals. ...

Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety

...ar stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). rapamune is a trademark of Wyeth Pharmaceuticals. ...

Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses

... Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). rapamune is a trademark of Wyeth Pharmaceuticals. CONTACT: Mariela Melendez of Cordis Corporation, phone, +1-786-313-2776,Cell: +1-786-218-4084, or E...

Cypher Sirolimus-eluting Coronary Stent Had Similar Results to Bypass Surgery in Long-Term Study of Patients With Multi-Vessel Coronary Artery Disease

...ar stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). rapamune is a trademark of Wyeth Pharmaceuticals. CONTACT: Mariela Melendez, Cordis Corporation, +1-786-313-2776, Cell:+1-786-218-4084, ; Todd Ringler, Edelm...

Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to Bypass Surgery and Better Outcomes Than Bare Metal Stents in Subgroup Analysis of Diabetic Patients With Multivessel Coronary Disease

...nting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). rapamune is a trademark of Wyeth Pharmaceuticals. CONTACT: Mariela Melendez of Cordis Corporation, +1-786-218-4084,; or Todd Ringler of Edelman, +1-617-8...

New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings

...ar stenting. Sirolimus, the active drug released for the stent, is marketed by Wyeth Pharmaceuticals, a division of Wyeth, under the name Rapamune(R). rapamune is a trademark of Wyeth Pharmaceuticals. SOURCE Cordis Corporation Mariela Melendez of Cordis Corporation, +1-786-313-2776, cell, +1-786-218-4084...